Expertise in
26
conditions

Dr. Tarek I. Hassanein

Gastroenterology
San Clemente, CA 
On Staff At
Offers Telehealth
44 Years of Experience
Expertise in
26
conditions
San Clemente, CA 

Overview

Tarek Hassanein is a Gastroenterologist in San Clemente, California. Dr. Hassanein has been practicing medicine for over 44 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Non-Alcoholic Fatty Liver Disease, Endoscopy, and Liver Transplant.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Alexandria Faculty Of Medicine , 1982, 1982

Residency

University of Alexandria Faculty of Medicine , Internal Medicine , 1984 - 1987

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Pittsburgh Medical Center , Hepatology , 1992 - 1994

Hospital Affiliations

Grossmont Hospital
Scripps Mercy Hospital
Sharp Coronado Hospital And Hlthcr Ctr
Sharp Chula Vista Medical Center
Uc San Diego Health Hillcrest - Hillcrest Med Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Southern California Liver Centers Inc
San Clemente, CA 92673

Additional Areas of Focus

Dr. Hassanein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Combination product
Study Phase: Not Applicable
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA And/or OCA
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drug: CNP-104
Study Phase: Phase 1/Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects With Varying Degrees of Cirrhosis
An Open-Label, Two-Part, Phase 1/2a, Crossover Study to Determine the Absolute Bioavailability and Pharmacokinetics of Oral Immediate-Release Doses of OCR-002 in Subjects With Varying Degrees of Cirrhosis
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Enrollment Status: Withdrawn
Publish Date: August 30, 2021
Intervention Type: Drug, Device
Study Phase: Early Phase 1
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
Enrollment Status: Terminated
Publish Date: January 25, 2019
Intervention Type: Biological, Other
Study Phase: Phase 3
View 14 Less Clinical Trials

83 Total Publications

Steroid therapy is linked to lower incidence of acute kidney injury in patients with severe alcohol-associated hepatitis.
Steroid therapy is linked to lower incidence of acute kidney injury in patients with severe alcohol-associated hepatitis.
Journal: Scientific reports
Published: August 22, 2025
Similar Doctors
William Sandborn
Expertise in
15
conditions
Dr. William Sandborn
Gastroenterology
Expertise in
15
conditions
Dr. William Sandborn
Gastroenterology

Office

9350 Campus Point Dr Ste 2B, 
La Jolla, CA 
 (11.8 miles away)
619-543-2347
Languages Spoken:
English
See accepted insurances

William Sandborn is a Gastroenterologist in La Jolla, California. Dr. Sandborn is highly rated in 15 conditions, according to our data. His top areas of expertise are Crohn's Disease, Hemorrhagic Proctocolitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology
Expertise in
21
conditions
Dr. Norah Terrault
Gastroenterology

Los Angeles-Gi Liver Clinic

1510 San Pablo St Ste 200, 
Los Angeles, CA 
 (111.0 miles away)
323-442-8894
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Norah Terrault is a Gastroenterologist in Los Angeles, California. Dr. Terrault is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

Expertise in
13
conditions
Dr. Rena Yadlapati
Gastroenterology
Expertise in
13
conditions
Dr. Rena Yadlapati
Gastroenterology

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (12.8 miles away)
619-543-2347
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rena Yadlapati is a Gastroenterologist in La Jolla, California. Dr. Yadlapati is highly rated in 13 conditions, according to our data. Her top areas of expertise are Gastroesophageal Reflux Disease (GERD), Achalasia, Heartburn, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Tarek I. Hassanein

How do I make an appointment with Dr. Tarek I. Hassanein?

You can book an appointment with Dr. Tarek I. Hassanein by calling their office at 619-522-0399. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tarek I. Hassanein a top-rated expert for Hepatitis C?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tarek I. Hassanein is classified as an Elite expert for Hepatitis C, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tarek I. Hassanein specialize in?

While Dr. Tarek I. Hassanein is a Gastroenterology, they have specific expertise in Hepatitis C, Hepatitis, and Non-Alcoholic Fatty Liver Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Tarek I. Hassanein participate in research or clinical trials?

Yes. Dr. Tarek I. Hassanein has published 83 articles and abstracts on conditions like Hepatitis C. You can view a list of Dr. Tarek I. Hassanein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tarek I. Hassanein accept my insurance?

Dr. Tarek I. Hassanein accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 619-522-0399 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hassanein's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 9 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile